Voyager Therapeutics (VYGR) Net Cash Flow (2014 - 2026)

Voyager Therapeutics has disclosed Net Cash Flow across 13 years of filings, most recently posting -$22.0 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$22.0 million, down 748.94% year-over-year; the trailing twelve-month figure through Mar 2026 was -$31.6 million (up 53.78% YoY), and the FY2025 annual result was -$6.2 million, down 261.34% from the prior year.
• Net Cash Flow came in at -$22.0 million for Q1 2026 at Voyager Therapeutics, down from $17.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $169.4 million in Q1 2023 to a low of -$179.0 million in Q3 2023.
• The 5-year median for Net Cash Flow is $3.4 million (2025), against an average of -$4.3 million.
• Across the five-year window, Net Cash Flow tumbled 119673.33% in 2022 and surged 1072.87% in 2023, its largest moves.
• Voyager Therapeutics' Net Cash Flow stood at $2.1 million in 2022, then soared by 68.32% to $3.5 million in 2023, then sank by 1264.96% to -$41.2 million in 2024, then soared by 142.03% to $17.3 million in 2025, then sank by 227.11% to -$22.0 million in 2026.
• The last three Net Cash Flow figures came in at -$22.0 million (Q1 2026), $17.3 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.